Sana Biotechnology, Inc. highlighted that Nature Biotechnology has published a paper titled "Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain." This paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) - the cells that give rise to the glial support cells of the brain - were transplanted into adult mice that had been neonatally transplanted with mutant Huntingtin (mHTT)-expressing hGPCs, the healthy cells outcompeted and eliminated the diseased glia, ultimately repopulating the brain with the healthy transplanted cells. These data establish an additional proof-of-concept for the development of SC379, Sana's pluripotent stem cell- derived GPC product candidate, as a potential therapy to deliver healthy allogeneic GPCs to patients with certain central nervous system disorders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 USD | -7.92% |
|
-26.85% | +28.19% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.19% | 1.26B | |
+35.14% | 51.07B | |
-7.43% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.63% | 26.35B | |
-17.77% | 19.46B | |
+40.52% | 13.58B | |
+30.70% | 12.46B | |
-3.41% | 11.75B |
- Stock Market
- Equities
- SANA Stock
- News Sana Biotechnology, Inc.
- Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions